Subgroup analyses of the effectiveness of oral glucosamine for knee and hip osteoarthritis; a systematic review and individual patient data meta-analysis from the OA Trial Bank


Runhaar J (corresponding author)
Post-doctoral Researcher
Erasmus University Medical Center Rotterdam
Department of General Practice
Room NA19-06
PO-box 2040, 3000 CA Rotterdam, the Netherlands
j.runhaar@erasusmc.nl

Rozendaal RM
Post-doctoral Researcher
Erasmus University Medical Center Rotterdam
Department of General Practice
PO-box 2040, 3000 CA Rotterdam, the Netherlands

van Middelkoop M
Assistant Professor
Erasmus University Medical Center Rotterdam
Department of General Practice
PO-box 2040, 3000 CA Rotterdam, the Netherlands

Bijlsma JW
Professor of Rheumatology
University Medical Center Utrecht
Department of Rheumatology & Clinical Immunology
PO-box 85500, 3508 GA Utrecht, the Netherlands

Doherty M
Professor of Rheumatology
The University of Nottingham, City Hospital
Academic Rheumatology Department
Hucknall Road NGS 1PB, Nottingham, UK

Dziedzic KS
Arthritis Research UK Professor of Musculoskeletal Therapies
NIHR Knowledge Mobilisation Research Fellow
Keele University
Department of Primary Care & Health Services
Staffordshire ST5 5BG, United Kingdom

Lohmander LS
Professor of Orthopaedics
Lund University
Medical Faculty, Department of Clinical Sciences, Orthopaedics
221 85 Lund, Sweden

McAlindon TE
Professor of Medicine
Tufts Medical Center
Division of Rheumatology
800 Washington Street, Boston, MA, 02111 USA

Zhang W
Professor of Epidemiology
The University of Nottingham, City Hospital
Academic Rheumatology Department
Hucknall Road NG5 1PB, Nottingham, UK

Bierma-Zeinstra S
Professor of Osteoarthritis and Related Disorders
Erasmus University Medical Center Rotterdam
Department of General Practice and Department of Orthopaedics
PO-box 2040, 3000 CA Rotterdam, the Netherlands
Abstract

Objective: To evaluate the effectiveness of oral glucosamine in subgroups of people with hip or knee osteoarthritis (OA) based on baseline pain severity, BMI, sex, structural abnormalities and presence of inflammation, using individual patient data.

Methods: After a systematic search of the literature and clinical trial registries, all randomized controlled trials (RCTs) evaluating the effect of any oral glucosamine substance in patients with clinically or radiographically defined hip or knee OA were contacted. As a minimum, pain, age, sex and BMI at baseline and pain as an outcome measure needed to be assessed.

Results: Of 21 eligible studies, six (N=1663) shared their trial data with the OA Trial Bank. Five trials (all independent of industry, N=1625) compared glucosamine to placebo, representing 55% of the total number of participants in all published placebo-controlled RCTs. Glucosamine was no better than placebo for pain or function at short (3 months) and long-term (24 months) follow-up. Glucosamine was also no better than placebo among the predefined subgroups. Stratification for knee OA and type of glucosamine did not alter these results.

Conclusions: Although proposed and debated for several years, open trial data are not widely made available for studies of glucosamine for OA, especially those sponsored by industry. Currently there is no good evidence to support the use of glucosamine for hip or knee OA and an absence of evidence to support specific consideration of glucosamine for any clinically relevant OA subgroup according to baseline pain severity, BMI, sex, structural abnormalities, or presence of inflammation.

Keywords: Osteoarthritis, glucosamine, individual patient data, meta-analysis, subgroups
Introduction

Oral glucosamine has long been recommended for the treatment of knee and hip osteoarthritis (OA). However, recent guidelines by OARSI 1 and NICE 2 highlight the lack of support for the efficacy of oral glucosamine for the management of symptoms or disease modification in OA 3. With increasing study quality over the past decades, reported effect sizes for glucosamine have decreased 4. Furthermore, methodological issues in trials studying the effect of glucosamine for OA symptoms, such as inadequate allocation concealment and absence of intention-to-treat analyses, has resulted in overestimation of its effectiveness 5. A network meta-analysis from 7 high-quality, large (>200 participants per trial) randomized controlled trials (RCTs) concluded that oral glucosamine was not superior to placebo in reducing OA pain or reduction in joint space narrowing3.

Notwithstanding the overall lack of efficacy of glucosamine, it is possible that certain subgroups of OA might respond differently (either better or worse) to any specific treatment 6. These subgroups might be based on different pathologies underlying the clinical presentation of OA, different disease stages, or on the presence of different co-morbidities 6. Accordingly, clinical guidelines increasingly call for the identification of any predictors of response to different treatment modalities 7. Since the effectiveness of glucosamine varies among different populations 4,5,8, it is possible that glucosamine might show higher efficacy when targeted at specific subgroups.

Recently, van Middelkoop et al. 9 reported on the methodology and legal structure to perform individual patient data (IPD) meta-analyses to identify clinically relevant subgroups that may show differential response to different OA treatments (the OA Trial Bank). The proposed methodologically robust method tests subgroup-treatment interaction effects using IPD from multiple published trials and allows for adjustment for confounding at both study and individual patient levels 9. Using this method, increased short-term efficacy for glucocorticoid treatment among knee OA patients with more severe pain has been demonstrated 10.

The present study aimed to collect IPD of all RCTs performed for oral glucosamine in people with knee and hip OA to evaluate the efficacy within predefined subgroups of OA based on pain severity, BMI, sex, structural abnormalities and presence of inflammation.

Methods

Systematic search
To identify all available RCTs, a systematic search of the literature was performed in Pubmed, the Cochrane Central Register of Controlled Trials, Embase, Web of Science, Cinahl and Scopus. The search strategy was based on the search protocol of the Cochrane publication on the effectiveness of glucosamine 8. It was adjusted for the different databases and limited to publications from 1994 because of the likelihood of communicating with corresponding authors and data being available (searched up to March 2014 and available upon request). Reference lists were hand searched for further identification of published work. Additional potential on-going studies were searched for in clinical trial registries.

Two authors (JR and RR) independently selected citations based on titles and abstracts. Subsequently full articles were obtained for those citations thought to fulfil the inclusion criteria and were independently assessed by the two review authors. A third review author was consulted if consensus was not reached (MvM). No protocol was registered for the current project, but full protocol details for the systematic review and the IPD meta-analysis were pre specified in the data delivery license.
agreement, that was approved by all members of the OA Trial Bank Steering Committee before the systematic search of the literature was initiated (available upon request).

Inclusion/exclusion criteria
All RCTs evaluating the effect of any oral glucosamine substance in participants with knee or hip OA were included. This included studies testing the effects of glucosamine within a subgroup of participants with OA. Studies solely testing a combination of glucosamine with another substance (e.g. chondroitin) were not included. There was no language restriction.

Participants
Participants were men and/or women with a diagnosis of OA of the knee or hip:
(1) according to ACR classification criteria, or
(2) on the basis of detailed clinical and/or radiographic information.
Studies including a subgroup of knee or hip OA patients were also included, because individual patient data were collected.

Interventions
All comparisons between different oral glucosamine doses or between different frequencies of intake were included. Co-interventions were allowed as long as they were identically applied to the glucosamine and control group.

 Comparator
All comparisons between oral glucosamine and any placebo/medication/dietary supplement/other non-surgical treatment were included.

Outcomes
The minimum criterion for inclusion of RCTs was adequate reporting of pain as an outcome measure.

Baseline predictors
(1) Important data:
As a minimum, severity of pain, age, sex and BMI should have been assessed at baseline in order to define subgroups.
(2) If available:
Signs of inflammation, either by physical examination (warmth, effusion) or by additional testing (ultrasound, MRI, biopsy, serum CRP/ESR), and structural abnormalities by radiography or magnetic resonance imaging (MRI) at baseline.

Data collection, transfer and checks
All corresponding authors of eligible trials were approached and asked to share trial data (first by email, subsequently by telephone). When corresponding authors could not be reached, the other listed authors and the institutes in which the trials had been performed were contacted. All data-deliverers willing to participate (i.e. the research institutes who own the data) were asked to sign the data delivery license agreement, including items on input data, obligations, ownership of data, terms, authorship, all subgroup analyses and publications. All anonymous data were transferred to a secured database at the Erasmus University Medical Center Rotterdam. Upon receiving the data, a thorough check of the data took place by reproducing the main baseline characteristics and the
reported changes over time for the available outcome measures. Uncertainties were resolved in collaboration with the trialists.

Risk of Bias assessment
The methodological quality of all included trials in the OA Trial Bank were assessed using the twelve criteria recommended by Cochrane (see supplementary Table S1) and were evaluated independently by two researchers (JR and RR). The criteria were scored as ‘yes’ (low risk of bias), ‘no’ (high risk of bias) or ‘unclear’. Any disagreement between the review authors was resolved by discussion, including input from a third review author (MvM). A study with a low risk of bias was defined as fulfilling six or more of the criteria items. In case the number of shared studies would allow proper interpretation (≥10 studies), funnel plots were considered for evaluation of publication bias.

Data analyses
Firstly, heterogeneity of the eligible studies was determined for the primary outcomes, using a 2-stage meta-analysis approach in Review Manager 5.3. In case of high heterogeneity ($I^2$ index > 50), sensitivity analyses without data from trials causing the heterogeneity were planned. Secondly, a descriptive comparison between studies was performed. We assumed missing data to be missing at random. Therefore missing data for covariates and outcome measures were imputed, using multiple imputation methods, within each original study. Outcomes measured on different scales were standardized in order to pool the data. Predefined subgroup factors were dichotomized, based on consensus of the OA Trial Bank Steering Committee. For this, descriptive statistics of the subgroup variables for each of the five trials were shared with the Steering Committee, together with proposed cut-off values, based on literature, data separation in the available trials and previous IPD meta-analysis by the OA Trial Bank.

The primary outcome measures were pain severity in the short-term (3 to 6 months) and at long-term (≥ 1 year) follow-up. Secondary outcomes were physical function and all forms of structural changes at these time points.

A one-stage multilevel regression analysis was performed to estimate the magnitude of the effect (estimated pooled mean differences) of glucosamine over the control intervention over all included studies and in the different subgroups with the individuals nested within each study. A single covariate was added to the regression models to indicate the study (fixed factor), in order to adjust for possible residual confounding by study differences. To assess possible subgroup effects, a random-effects linear regression model was used to determine interaction effects. This model included the dependent variable (primary or secondary outcome measure), the independent variable (treatment group), the effect modifier (subgroup indicator), and an interaction term (independent variable x effect modifier). All analyses were adjusted for age sex, BMI, WOMAC pain at baseline and were performed with and without stratification for type of glucosamine and with and without stratification for the affected joint. Comparisons and subgroup analysis for which only one RCT was available were not taken into account, since main effects were already studied in the original publication and individual trials usually were not powered for subgroup analysis. A p-value < 0.05 was regarded as statistically significant in all analyses, using IBM SPSS software version 22.

Results
The literature search resulted in 1377 abstracts. After screening, 58 publications were evaluated in full-text and 18 fulfilled all inclusion criteria, with two additional trials identified from the
references of the included trials \(^{30, 31}\) (Figure 1). Searching the clinical trial registries resulted in one additional potentially eligible trial (NCT01074476). All 21 corresponding authors of these trials were contacted for participation. After multiple efforts to contact all data owners of the eligible trials, authors/institutes of six studies agreed to participate and delivered trial data to the OA Trial Bank \(^{14-16, 24, 28, 29}\). Corresponding authors of two trials indicated that trial data were no longer available \(^{13, 23}\). Two corresponding authors did reply positively to the initial request for data sharing, but a signed license agreement was never received \(^{12, 20}\). One corresponding author was not interested in participation \(^{17}\). No contact was established with any of the authors nor the research institutes of five studies \(^{18, 21, 26, 30, 31}\) and the one study identified in the clinical trial registry. Four data owners indicated that they were not permitted to share their data by the study sponsor \(^{10, 22, 25, 27}\). See Table 1 for full details of all eligible studies.

Five out of the six studies willing to participate involved knee OA participants \(^{14-16, 24, 29}\), while only one involved hip OA participants \(^{28}\). Follow-up duration in the six trials ranged from 3 to 24 months. Three studies evaluated glucosamine sulphate (GS) \(^{15, 16, 28}\) and two glucosamine hydrochloride (GH) \(^{14, 29}\). The publication of the remaining study stated that the first 163 subjects received GS, but that the subsequent subjects received GH \(^{24}\). However, after extensive communication with the trial owner, the order of glucosamine type was deemed to be a typographical error, since the supplier of the glucosamine for the latter part of the participants (Rottapharm) is renowned for its GS. Data on participants within this trial were allocated to the stratified analysis for glucosamine type based upon this new insight of the glucosamine type provided. With the exception of the trial by Coulson et al. that used green-lipped mussel extract as comparison \(^{15}\), all studies compared their glucosamine substrate against placebo. The trial by Coulson et al. was therefore not included in the subgroup analysis (mean change in WOMAC pain -1.6 [-3.7 to 0.6] on a 0 to 20 scale in favour of glucosamine \([p = 0.157]\)) \(^{15}\). The trial by Sawitzke et al. \(^{29}\) presented long-term follow-up from the Clegg et al. \(^{14}\), but since both publications report on different outcome measures of interest (clinical data and radiography vs. clinical data only) and risk of bias could be assessed for both publications separately, both were indicated as separate trials. No important issues were identified when checking shared trial data, but for the trial by McAlindon \(^{24}\) for which data of the first 199 (out of 205 in the original publication) could be retrieved by the trial owners. No relevant differences in baseline characteristics for the subjects with shared data and the published data were observed. Percentages of missing data for the main baseline characteristics and all outcome measures for each of the five individual trials are presented in supplementary Table S2. All listed variables were used in the multiple imputation by the SPSS software package, creating 20 imputed data sets for each trial.

The five trials included in the analysis included a total number of 1625 participants (64% women), 815 randomised to glucosamine and 810 to placebo. This reflected 55% of the participants randomized in the 17 published RCTs on glucosamine versus placebo. Pain was measured in all five studies using the ordinal WOMAC questionnaire \(^{32}\). Scores were rescaled to a 0-100 scale and defined at short-term (closest to a minimal of 3 months follow-up) for the trials by McAlindon et al. \(^{24}\), Clegg et al. \(^{14}\), and Rozendaal et al. \(^{28}\) and long-term (2 years follow-up) for Fransen et al. \(^{15}\), Sawitzke et al. \(^{29}\), and Rozendaal et al. \(^{28}\). Physical function was also measured in all five studies using the WOMAC questionnaire and was rescaled and defined in an identical matter. Figure 2 presents the overall mean differences of these five trials for the primary outcome at short and long-term, based on the imputed data sets.
The following subgroups were defined: WOMAC pain <70 vs. ≥70, BMI <27 kg/m² vs. ≥27 kg/m², Kellgren & Lawrence grade⁴³ (KL) 0-2 vs. KL3-4, and presence vs. absence of inflammation. Presence of inflammation was defined as either presence of swelling/effusion on clinical examination¹⁴, ²⁹ or an elevated erythrocyte sedimentation rate (ESR)²⁸, defined as ESR ≥20 mm/h for men aged ≥50 years, ESR ≥15 mm/h for men aged <50 years, ESR ≥30 mm/h for women aged ≥50 years, and ESR ≥20 mm/h for women aged <50 years. Inflammation data were only available when combining data from one knee OA¹⁴, ²⁹ and one hip OA trial²⁸. Therefore, no additional stratification was possible. Baseline Kellgren and Lawrence grades were only available in one knee OA trial with short-term outcomes¹⁴, two knee OA trials with long-term outcomes¹⁶, ²⁹, and the one hip OA trial²⁸ with short and long-term outcomes. Given this lack of consistency, stratification of the subgroup analysis was done for knee OA trials only on long-term outcomes.

Risk of bias and heterogeneity
All five studies were defined as having a low risk of bias (Table 2) and heterogeneity was low ($I^2 = 0$ for main effects on pain at short and $I^2 = 14$ for long-term follow-up, see Figure 2), so no sensitivity analyses were performed.

Overall intervention effects
Estimated pooled differences for the primary and secondary outcome measures are presented in Table 3. No statistical significance main effects were found for glucosamine over placebo.

Subgroup effects
None of the interaction terms of the predefined subgroups reached statistical significance (see Table 3). Estimated pooled differences within each subgroup for the primary outcomes over all eligible trials are presented in Figure 3. Within the stratified analyses among studies using GS for knee OA the number of subjects with high baseline pain was too small for the software to test the pooled interaction term for the baseline pain severity subgroup.

Discussion
To our knowledge, this is the first IPD meta-analysis to examine potential subgroup effects of oral glucosamine for people with OA. Within the 5 trials where the authors were willing to share their data, 1625 patients with knee or hip OA were analysed. This represents 55% of all available participants from the placebo controlled trials for this product. The main findings are: [1] overall, glucosamine was no better than placebo for both pain and function outcomes; [2] in subgroup analyses, glucosamine was no better than placebo according to baseline pain severity, BMI, gender, structural abnormalities, and presence of inflammation; and [3] the majority of trials were knee OA (4 trials, 1403 patients) and the analysis based on knee OA only had similar results.

Several systematic reviews and network meta-analyses have shown that as the number of high-quality and industry-independent studies on the effectiveness of glucosamine for OA increased over time, the results of earlier studies that showed beneficial effects of glucosamine were viewed as less credible⁴⁻⁵, ⁸, ³⁴, ³⁵. It is therefore not surprising that the present IPD meta-analysis also showed no significant main effects, especially since previous studies showed a low risk of bias to be associated with small, non-significant effect sizes for glucosamine over placebo ³, ⁸, ³⁴ and the fact that all included studies had a low risk of bias. Present results of overall treatment effects within the trials that shared data and over the different stratifications ranged from -0.43 to 2.02 on the 0 to 100 WOMAC pain scale, which is comparable to the overall treatment effects for industry independent
studies (0.1 [95% CI -0.2 to 0.5] for VAS pain on a 0 to 10 scale) presented by the meta-analyses of Wandel and colleagues\(^3\). In the literature, overall beneficial effects of treatment have been reported in studies using the glucosamine compound produced by Rottapharm \(^4,5,8,34\), however these trials were not made available to the study team for the current analyses.

Extending previous initiatives, the present study also evaluated treatment effects of glucosamine over placebo for several clinically relevant subgroups of OA, made possible by the IPD from the collaborating trials. Despite the large number of participants incorporated in the IPD meta-analysis, none of the interaction terms reached statistical significance. The interactions with BMI among knee OA patients receiving GS on short-term function (\(p = 0.12\)) and on long-term pain (\(p = 0.10\)) were the only outcomes for which further research may be warranted. However, given the number of analyses performed in the study incidental findings are certainly possible.

The currently used cut-off for the baseline pain severity subgroup is somewhat comparable to the strata used in the Clegg et al. study\(^14\) to test for different effects within subjects with mild pain (WOMAC pain scores 0 to 60) versus those with moderate to severe pain (WOMAC pain scores 60 to 80). The Clegg et al. study was not powered to show subgroup effects, but the non-significant effects of glucosamine over placebo within both subgroups is corroborated by the present results.

The current study has several limitations. Despite all efforts, data from only six of the 21 identified studies were acquired. Of those studies not included in the present study, the largest groups were those not responding to any of the requests for data sharing (6 studies) and those not permitted by the commercial study sponsor to share data (4 studies), see Table 1. Although missing data for the main baseline characteristics within the data shared with the OA Trial Bank were limited, multiple imputation methods were needed to deal with the missing data in the outcome measures that ranged from 2% to 46%. Within the trials that shared data, only a few measured the pre-defined subgroups based on structural abnormalities and presence of inflammation. The available data for these subgroups combined studies evaluating different glucosamine substances for different OA joints. Therefore, rigorous stratification of the analysis was not possible with the available data.

Open access to data of clinical trials has been proposed and debated for several years\(^36\text{--}38\). Nevertheless our experience, in common with others, suggests that currently this is far from accepted practice\(^39\). Thus the full potential and use of completed clinical trials is not reached and only part of the clinical evidence is available to clinicians and patients, thus threatening the appropriateness of recommendations for clinical decision-making\(^39\). Once initiatives such as the OA Trial Bank, which appropriately use existing data for scientific purposes, become more established and generally accepted, authors and commercial parties involved in clinical research may become more confident in data sharing. The OA Trial Bank plans to update publications every five years and will again approach data owners that chose to not share their data to the OA Trial Bank in the first initiative.

The aim of the present study was to perform an IPD meta-analysis on all available RCTs on glucosamine in people with OA. After performing the systematic search of the literature and clinical trial registers, it took 18 months to reach as many data owners as possible and to collect and check all data of those willing to deliver their trial data. For a systematic review, one might argue that an update of the search strategy is warranted. However, given the time-consuming efforts of sharing data between research institutes, this was not feasible for the present study.
In conclusion, the current IPD on the efficacy of glucosamine for subgroups of OA based on pain severity, BMI, sex, radiographic structural changes, and presence of inflammation, using data from 55% of the participants available in literature and using data from low risk-of-bias trials only, did not identify a subgroup for which glucosamine showed any significant beneficial effects over placebo for pain or function in either the short- or long-term. Stratification only for participants with knee OA or for type of glucosamine did not result in any differences in outcomes. Therefore, currently there is no evidence to support the use of glucosamine for treatment of hip or knee OA in general, and an absence of evidence to support the use of glucosamine for clinically relevant subgroups of OA according to baseline pain severity, BMI, sex, structural abnormalities, and presence of inflammation.

Acknowledgements
All data owners (researchers and institutes) are to be acknowledged for providing their data to the OA Trial Bank.

Funding sources
The current project received funding by the Dutch Arthritis Foundation (BP12-1-161). KSD is part funded by the National Institute for Health Research (NIHR) Collaborations for Leadership in Applied Research and Care West Midlands and by a Knowledge Mobilisation Research Fellowship (KMRF-2014-03-002) from the NIHR. This paper presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. WZ is supported by a grant from Arthritis Research UK. TEM is supported by grants from Sanofi Aventis, Abbvie, Fidia, Samumed, and Pfizer and personal fees from Flexion Therapeutics, Samumed, Plexxikon Inc, Regeneron, Orthogen, and McNeil Consumer HC. LSL is supported by personal fees from Galapagos NV, Flexion Therapeutics, Johnson & Johnson, Regeneron, Össur, and Samumed.

Role of the funding bodies
None of the funding bodies had a role in the study design, in the collection, analysis and interpretation of the data, in writing of the manuscript, or in the decision to submit the manuscript for publication.

Competing interest
All authors have completed the ICMJE uniform disclosure form and declare no financial relationships with any organisations that might have an interest in the submitted work.

Contributions to the work
JR, MvM, JWB, MD, KSD, LSL, TEM, WZ and SBZ have substantially contributed to the conception and design of the work. JR and RR have substantially contributed to the acquisition of the data and drafted the manuscript. All authors contributed to the analysis and interpretation of the work, revised the manuscript critically for important intellectual content, approved the final version of the manuscript, and agreed to be accountable for all aspects of the work.

Study data
All authors had full access to all of the data and can take responsibility for the integrity of the data and the accuracy of the analysis. Individual Patient Data from included studies only available upon approval of the trial owners and the Steering Committee of the OA Trial Bank.
Transparency declaration
JR, MvM and SBZ affirm that the manuscript is an honest, accurate, and transparent account of the study being reported. No important aspects of the study have been omitted and any discrepancy from the study as planned have been explained.

Patient involvement
Two representatives of patient and public involvement (members of the Arthritis research UK OA Research Users Group) are official members of the Steering Committee of the OA Trial Bank. These representatives provided feedback on the design of the study, including study selection, selection and definitions of subgroups, and outcome measures. Also for dissemination activities of OA Trial Bank and for prioritization of future research questions, the input from patient and public involvement is obtained.
Figure 1. Study flow chart

Figure 2. Forest plots for mean change in WOMAC pain at short-term (upper panel) and long-term (lower panel) on a 0 to 100 scale for studies that shared trial data.

Figure 3. Estimated pooled differences between glucosamine and placebo within pre-defined subgroups for all eligible trials. Positive values indicate a greater reduction in the outcome measure for glucosamine. Red figures represent low pain (WOMAC pain < 70), low BMI (< 27 kg/m²), male sex, K&L grades 0-2, and absence of inflammation subgroups, respectively. Blue figures represent high pain (WOMAC pain ≥ 70), high BMI (≥ 27 kg/m²), female sex, K&L grades 3-4, and presence of inflammation subgroups, respectively.
Table 1. Characteristics of all eligible and contacted studies (stratified for authors’ reply on data sharing request).

<table>
<thead>
<tr>
<th>Origin</th>
<th>Participants</th>
<th>N in control group</th>
<th>N in Glucosamine group</th>
<th>Interventions</th>
<th>Follow-up</th>
<th>Funding source</th>
<th>Reply to data sharing request</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clegg et al. 2006(^{14})</td>
<td>USA</td>
<td>knee OA</td>
<td>313</td>
<td>317</td>
<td>6 months</td>
<td>Funding agency</td>
<td>Data delivered to OA Trial Bank</td>
</tr>
<tr>
<td>Coulson et al. 2013(^{15})</td>
<td>Australia</td>
<td>knee OA</td>
<td>21</td>
<td>17</td>
<td>3 months</td>
<td>Commercial party</td>
<td>Data delivered to OA Trial Bank</td>
</tr>
<tr>
<td>Fransen et al. 2015(^{16})</td>
<td>Australia</td>
<td>knee OA</td>
<td>151</td>
<td>152</td>
<td>24 months</td>
<td>Governmental institution and by some supplementary funding from a commercial party</td>
<td>Data delivered to OA Trial Bank</td>
</tr>
<tr>
<td>McAlindon et al. 2004(^{24})</td>
<td>USA</td>
<td>knee OA</td>
<td>104</td>
<td>101</td>
<td>3 months</td>
<td>Funding agency</td>
<td>Data delivered to OA Trial Bank</td>
</tr>
<tr>
<td>Rozendaal et al. 2008(^{28})</td>
<td>The Netherlands</td>
<td>hip OA</td>
<td>111</td>
<td>111</td>
<td>24 months</td>
<td>Governmental institution</td>
<td>Data delivered to OA Trial Bank</td>
</tr>
<tr>
<td>Sawitzke et al. 2010(^{29^{*}})</td>
<td>USA</td>
<td>knee OA</td>
<td>131</td>
<td>134</td>
<td>24 months</td>
<td>Governmental institution</td>
<td>Data delivered to OA Trial Bank</td>
</tr>
<tr>
<td>Cibere et al. 2004(^{13})</td>
<td>Canada</td>
<td>knee OA</td>
<td>66</td>
<td>71</td>
<td>6 months</td>
<td>Funding agency</td>
<td>Data no longer available</td>
</tr>
<tr>
<td>Martí-Bonmatí et al. 2009(^{23})</td>
<td>Spain</td>
<td>knee OA</td>
<td>4</td>
<td>7</td>
<td>6 months</td>
<td>Commercial party</td>
<td>Data no longer available</td>
</tr>
<tr>
<td>Chopra et al. 2011(^{12})</td>
<td>India</td>
<td>knee OA</td>
<td>35</td>
<td>35</td>
<td>4 months</td>
<td>Governmental institution</td>
<td>Positive to first request, but no data delivery</td>
</tr>
<tr>
<td>Study Name and Reference</td>
<td>Country</td>
<td>Syndrome</td>
<td>N</td>
<td>N</td>
<td>Intervention</td>
<td>Duration</td>
<td>Funding</td>
</tr>
<tr>
<td>--------------------------</td>
<td>---------</td>
<td>----------</td>
<td>---</td>
<td>---</td>
<td>--------------</td>
<td>----------</td>
<td>---------</td>
</tr>
<tr>
<td>Hughes and Carr 2002²⁰</td>
<td>UK</td>
<td>knee OA</td>
<td>40</td>
<td>40</td>
<td>GS vs. placebo</td>
<td>6 months</td>
<td>Unknown</td>
</tr>
<tr>
<td>Frestedt et al. 2008¹⁷</td>
<td>USA</td>
<td>knee OA</td>
<td>16</td>
<td>19</td>
<td>GS vs. Placebo vs. Aquamin vs. Aquamin+GS</td>
<td>3 months</td>
<td>Commercial party</td>
</tr>
<tr>
<td>Giordano et al. 2009³¹</td>
<td>Italy</td>
<td>knee OA</td>
<td>30</td>
<td>30</td>
<td>GS vs. placebo</td>
<td>3 months</td>
<td>Unknown</td>
</tr>
<tr>
<td>Hatano et al. 2006¹⁸</td>
<td>Japan</td>
<td>knee OA</td>
<td>31</td>
<td>36</td>
<td>Soymilk with vs without N-acetyl glucosamine</td>
<td>3 months</td>
<td>Unknown</td>
</tr>
<tr>
<td>Kawakasi et al. 2008²¹</td>
<td>Japan</td>
<td>knee OA</td>
<td>42</td>
<td>49</td>
<td>Home exercise vs. home exercise+GH vs. home exercise+risedronate</td>
<td>18 months</td>
<td>Unknown</td>
</tr>
<tr>
<td>NCT01074476*</td>
<td>Canada</td>
<td>knee OA</td>
<td>10</td>
<td>10</td>
<td>GS vs. placebo</td>
<td>3 months</td>
<td>Governmental institution</td>
</tr>
<tr>
<td>Petersen et al. 2011¹⁶</td>
<td>Denmark</td>
<td>knee OA</td>
<td>12</td>
<td>12</td>
<td>GS vs. placebo vs. ibuprofen</td>
<td>3 months</td>
<td>Governmental institution, and funding agency</td>
</tr>
<tr>
<td>Usha and Naidu 2004³⁰</td>
<td>India</td>
<td>knee OA</td>
<td>28</td>
<td>30</td>
<td>G vs. MSM vs. G + MSM vs. placebo</td>
<td>3 months</td>
<td>Commercial party</td>
</tr>
<tr>
<td>Herrero-Beaumont et al. 2007¹⁹</td>
<td>Spain/Portugal</td>
<td>knee OA</td>
<td>104</td>
<td>106</td>
<td>Crystalline GS vs. placebo vs. acetaminophen</td>
<td>6 months</td>
<td>Commercial party</td>
</tr>
<tr>
<td>Kwoh et al. 2014²¹</td>
<td>USA</td>
<td>knee OA</td>
<td>103</td>
<td>98</td>
<td>GH vs. placebo</td>
<td>6 months</td>
<td>Commercial party</td>
</tr>
<tr>
<td>Study</td>
<td>Country</td>
<td>Disease</td>
<td>N</td>
<td>N</td>
<td>Treatment</td>
<td>Duration</td>
<td>Sponsor</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-------------</td>
<td>------------</td>
<td>---</td>
<td>---</td>
<td>------------------------------------------</td>
<td>----------</td>
<td>--------------</td>
</tr>
<tr>
<td>Pavelká et al. 2002&lt;sup&gt;25&lt;/sup&gt;</td>
<td>Czech Republic</td>
<td>knee OA</td>
<td>101</td>
<td>101</td>
<td>Crystalline GS vs. placebo</td>
<td>36 months</td>
<td>Commercial party</td>
</tr>
<tr>
<td>Reginster et al. 2001&lt;sup&gt;27&lt;/sup&gt;</td>
<td>Belgium</td>
<td>knee OA</td>
<td>106</td>
<td>106</td>
<td>GS vs. placebo</td>
<td>36 months</td>
<td>Commercial party</td>
</tr>
</tbody>
</table>

2 *Trial identified in trial registry, no publication available; **long-term follow-up of Clegg et al.; ***The first 163 patients were randomized over placebo and glucosamine hydrochloride, the remaining subjects over placebo and glucosamine sulphate; N: number of patients randomized to the specific group; GS = glucosamine sulphate; GH = glucosamine hydrochloride; CS = chondroitin sulphate; G = unknown which glucosamine substance; MSM: methylsulfonylmethane.
### Table 2. Risk of bias assessment of studies included in glucosamine vs. placebo comparison.

<table>
<thead>
<tr>
<th>Study</th>
<th>A1</th>
<th>B2</th>
<th>C3</th>
<th>C4</th>
<th>C5</th>
<th>D6</th>
<th>D7</th>
<th>E8</th>
<th>E9</th>
<th>E10</th>
<th>E11</th>
<th>E12</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clegg et al. 2006 14</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>Low risk</td>
</tr>
<tr>
<td>Fransen et al. 2015 16</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>?</td>
<td>+</td>
<td>+</td>
<td>Low risk</td>
</tr>
<tr>
<td>McAlindon et al. 2004 24</td>
<td>?</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>Low risk</td>
</tr>
<tr>
<td>Rozendaal et al. 2008 28*</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>Low risk</td>
</tr>
<tr>
<td>Sawitzke et al. 2010 29</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>Low risk</td>
</tr>
</tbody>
</table>

+ yes (low risk of bias); - no (high risk of bias); ? unclear; A1. Method of randomization adequate; B2. Treatment allocation concealed; C3. Patient blinded to the intervention; C4. Care provider blinded to the intervention; C5. Outcome assessor blinded to the intervention; D6. Drop-out rate described and acceptable; D7. Randomized participants analysed in the group to which they were allocated; E8. Groups similar at baseline regarding the most important prognostic indicators; E9. Co-interventions avoided or similar; E10. Compliance acceptable; E11. Timing of the outcome assessment similar in all groups; E12 Selective outcome reporting. Overall, low risk of bias was defined as fulfilling six or more of the criteria items. *scored by JR and MvM due to study involvement of RR.
Table 3. Estimated pooled differences (95% CI) between glucosamine and placebo on a 0-100 scale (positive values indicate a greater reduction in the outcome measure for glucosamine) and p-values for treatment-subgroup interactions.

<table>
<thead>
<tr>
<th></th>
<th>All studies (N = 1625 in 5 studies)</th>
<th>Knee OA only (N = 1403 in 4 studies)</th>
<th>GH in knee OA (N = 1058 in 3 studies)</th>
<th>GS in knee and hip OA (N = 567 in 3 studies)</th>
<th>GS in knee OA (N = 345 in 2 studies)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Estimated pooled differences and 95% confidence interval</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucosamine vs placebo</td>
<td>0.60 (-1.80 to 3.00)</td>
<td>0.91 (-1.91 to 3.75)</td>
<td>0.98 (-1.94 to 3.91)</td>
<td>-0.43 (-4.44 to 3.58)</td>
<td>0.59 (-11.79 to 12.98)</td>
</tr>
<tr>
<td><strong>p-values for treatment-subgroup interactions</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pain subgroup</td>
<td>0.77</td>
<td>0.97</td>
<td>0.80</td>
<td>0.17</td>
<td>f</td>
</tr>
<tr>
<td>BMI subgroup</td>
<td>0.31</td>
<td>0.62</td>
<td>0.56</td>
<td>0.41</td>
<td>0.89</td>
</tr>
<tr>
<td>Sex subgroup</td>
<td>0.68</td>
<td>0.59</td>
<td>0.68</td>
<td>0.86</td>
<td>0.68</td>
</tr>
<tr>
<td>KL subgroup</td>
<td>0.75</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Inflammation subgroup</td>
<td>0.92</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

**Estimated pooled differences and 95% confidence interval**
Glucosamine vs placebo
-1.76 to 3.73 (-2.83 to 3.22) (-4.33 to 5.89) (-1.90 to 4.33) (-3.67 to 2.90)
**p-values for treatment-subgroup interactions**

<table>
<thead>
<tr>
<th></th>
<th>All studies (N = 1625 in 5 studies)</th>
<th>Knee OA only (N = 1403 in 4 studies)</th>
<th>GH in knee OA (N = 1058 in 3 studies)</th>
<th>GS in knee and hip OA (N = 567 in 3 studies)</th>
<th>GS in knee OA (N = 345 in 2 studies)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Estimated pooled differences and 95% confidence interval</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucosamine vs placebo</td>
<td>0.98 (-1.76 to 3.73)</td>
<td>0.19 (-2.83 to 3.22)</td>
<td>0.78 (-4.33 to 5.89)</td>
<td>1.22 (-1.90 to 4.33)</td>
<td>-0.38 (-3.67 to 2.90)</td>
</tr>
<tr>
<td><strong>p-values for treatment-subgroup interactions</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pain subgroup</td>
<td>0.26</td>
<td>0.28</td>
<td>0.42</td>
<td>0.44</td>
<td>0.86</td>
</tr>
<tr>
<td>BMI subgroup</td>
<td>0.55</td>
<td>0.10</td>
<td>0.51</td>
<td>0.72</td>
<td>0.10</td>
</tr>
<tr>
<td>Sex subgroup</td>
<td>0.46</td>
<td>0.53</td>
<td>0.75</td>
<td>0.52</td>
<td>0.77</td>
</tr>
<tr>
<td>KL subgroup</td>
<td>0.72</td>
<td>0.40</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Inflammation subgroup</td>
<td>0.23</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

**Estimated pooled differences and 95% confidence interval**
Glucosamine vs placebo
-0.45 to 3.96 (-0.81 to 4.04) (-0.77 to 4.61) (-2.11 to 4.57) (-10.88 to 10.09)
**p-values for treatment-subgroup interactions**

<table>
<thead>
<tr>
<th></th>
<th>All studies (N = 1625 in 5 studies)</th>
<th>Knee OA only (N = 1403 in 4 studies)</th>
<th>GH in knee OA (N = 1058 in 3 studies)</th>
<th>GS in knee and hip OA (N = 567 in 3 studies)</th>
<th>GS in knee OA (N = 345 in 2 studies)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Estimated pooled differences and 95% confidence interval</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucosamine vs placebo</td>
<td>1.74 (-0.45 to 3.96)</td>
<td>1.80 (-0.81 to 4.04)</td>
<td>1.92 (-0.77 to 4.61)</td>
<td>1.23 (-2.11 to 4.57)</td>
<td>-0.39 (-10.88 to 10.09)</td>
</tr>
<tr>
<td><strong>p-values for treatment-subgroup interactions</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pain subgroup</td>
<td>0.47</td>
<td>0.34</td>
<td>0.37</td>
<td>0.69</td>
<td>f</td>
</tr>
<tr>
<td>BMI subgroup</td>
<td>0.87</td>
<td>0.83</td>
<td>0.64</td>
<td>0.38</td>
<td>0.12</td>
</tr>
<tr>
<td>Sex subgroup</td>
<td>0.47</td>
<td>0.30</td>
<td>0.39</td>
<td>0.91</td>
<td>0.34</td>
</tr>
<tr>
<td>KL subgroup</td>
<td>0.96</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Inflammation subgroup</td>
<td>0.37</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

**Estimated pooled differences and 95% confidence interval**
Glucosamine vs placebo
-1.27 to 4.06 (-2.31 to 3.58) (-4.43 to 6.13) (-0.82 to 4.86) (-2.29 to 3.52)
**p-values for treatment-subgroup interactions**

<table>
<thead>
<tr>
<th></th>
<th>All studies (N = 1625 in 5 studies)</th>
<th>Knee OA only (N = 1403 in 4 studies)</th>
<th>GH in knee OA (N = 1058 in 3 studies)</th>
<th>GS in knee and hip OA (N = 567 in 3 studies)</th>
<th>GS in knee OA (N = 345 in 2 studies)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Estimated pooled differences and 95% confidence interval</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucosamine vs placebo</td>
<td>1.40 (-1.27 to 4.06)</td>
<td>0.63 (-2.31 to 3.58)</td>
<td>0.85 (-4.43 to 6.13)</td>
<td>2.02 (-0.82 to 4.86)</td>
<td>0.62 (-2.29 to 3.52)</td>
</tr>
</tbody>
</table>
measured using WOMAC pain (0-100) and adjusted for age, sex, BMI, WOMAC pain at baseline and study number. **measured using WOMAC function (0-100) and adjusted for age, sex, BMI, WOMAC function at baseline and study number. Positive estimated pooled differences indicate a greater reduction in the outcome in the glucosamine group compared to the placebo group. *WOMAC pain <70 vs. ≥70 on a 0-100 scale. BMI <27 kg/m² vs. ≥27 kg/m². c male vs. female. d Kellgren & Lawrence grades 0-2 vs. 3-4 (not available in McAlindon et al.24). e Presence of inflammation, defined as presence of swelling/effusion on clinical examination or an elevated erythrocyte sedimentation rate (ESR), defined as ESR ≥20 mm/h for men aged ≥50 years, ESR ≥15 mm/h for men aged <50 years, ESR ≥30 mm/h for women aged ≥50 years, and ESR ≥20 mm/h for women aged <50 years, vs. absence of inflammation (not available in McAlindon et al.24 and Fransen et al.16). f Too few cases in high pain group for the software to test the interaction term.
References


